Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Impact of Sex, Androgens, and Prostate Size on C57BL/6J Mouse Urinary Physiology: Functional Assessment.

Ruetten H, Wegner KA, Zhang HL, Wang P, Sandhu JK, Sandhu SK, Mueller B, Wang Z, Macoska J, Peterson RE, Bjorling DE, Ricke WA, Marker PC, Vezina CM.

Am J Physiol Renal Physiol. 2019 Aug 7. doi: 10.1152/ajprenal.00270.2019. [Epub ahead of print]

PMID:
31390231
2.

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.

Koivula RW, Forgie IM, Kurbasic A, Viñuela A, Heggie A, Giordano GN, Hansen TH, Hudson M, Koopman ADM, Rutters F, Siloaho M, Allin KH, Brage S, Brorsson CA, Dawed AY, De Masi F, Groves CJ, Kokkola T, Mahajan A, Perry MH, Rauh SP, Ridderstråle M, Teare HJA, Thomas EL, Tura A, Vestergaard H, White T, Adamski J, Bell JD, Beulens JW, Brunak S, Dermitzakis ET, Froguel P, Frost G, Gupta R, Hansen T, Hattersley A, Jablonka B, Kaye J, Laakso M, McDonald TJ, Pedersen O, Schwenk JM, Pavo I, Mari A, McCarthy MI, Ruetten H, Walker M, Pearson E, Franks PW; IMI DIRECT Consortium.

Diabetologia. 2019 Sep;62(9):1601-1615. doi: 10.1007/s00125-019-4906-1. Epub 2019 Jun 15.

3.

Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.

Margerie D, Lefebvre P, Raverdy V, Schwahn U, Ruetten H, Larsen P, Duhamel A, Labreuche J, Thuillier D, Derudas B, Gheeraert C, Dehondt H, Dhalluin Q, Alexandre J, Caiazzo R, Nesslany P, Verkindt H, Pattou F, Staels B.

BMC Med Genomics. 2019 Jun 3;12(1):80. doi: 10.1186/s12920-019-0536-1.

4.

Motivations for data sharing-views of research participants from four European countries: A DIRECT study.

Shah N, Coathup V, Teare H, Forgie I, Giordano GN, Hansen TH, Groeneveld L, Hudson M, Pearson E, Ruetten H, Kaye J.

Eur J Hum Genet. 2019 May;27(5):721-729. doi: 10.1038/s41431-019-0344-2. Epub 2019 Jan 30.

PMID:
30700834
5.

Sharing data for future research-engaging participants' views about data governance beyond the original project: a DIRECT Study.

Shah N, Coathup V, Teare H, Forgie I, Giordano GN, Hansen TH, Groeneveld L, Hudson M, Pearson E, Ruetten H, Kaye J.

Genet Med. 2019 May;21(5):1131-1138. doi: 10.1038/s41436-018-0299-7. Epub 2018 Sep 28.

PMID:
30262927
6.

Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.

Ruetten H, Gebauer M, Raymond RH, Calle RA, Cobelli C, Ghosh A, Robertson RP, Shankar SS, Staten MA, Stefanovski D, Vella A, Wright K, Fryburg DA; Foundation for the NIH Biomarkers Consortium Beta Cell Project Team.

Metab Syndr Relat Disord. 2018 Oct;16(8):406-415. doi: 10.1089/met.2018.0022. Epub 2018 Aug 17. Erratum in: Metab Syndr Relat Disord. 2019 Mar;17(2):128.

PMID:
30117761
7.

Outpatient versus inpatient mixed meal tolerance and arginine stimulation testing yields comparable measures of variability for assessment of beta cell function.

Shankar SS, Lee DS, Raymond RH, Calle RA, Cobelli C, Ghosh A, Robertson RP, Ruetten H, Staten MA, Stefanovski D, Vella A, Whitaker S, Fryburg DA; Foundation for the NIH Biomarkers Consortium Beta Cell Project Team.

Contemp Clin Trials Commun. 2018 Mar 29;10:94-99. doi: 10.1016/j.conctc.2018.03.009. eCollection 2018 Jun.

8.

Prostatic collagen architecture in neutered and intact canines.

Ruetten H, Wegner KA, Romero MF, Wood MW, Marker PC, Strand D, Colopy SA, Vezina CM.

Prostate. 2018 Aug;78(11):839-848. doi: 10.1002/pros.23641. Epub 2018 May 8.

9.

STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.

Assumpção ALFV, Jark PC, Hong CC, Lu Z, Ruetten HM, Heaton CM, Pinkerton ME, Pan X.

J Vet Intern Med. 2018 Jan;32(1):361-369. doi: 10.1111/jvim.14860. Epub 2017 Nov 9.

10.

Type-2 diabetes-associated variants with cross-trait relevance: Post-GWAs strategies for biological function interpretation.

Frau F, Crowther D, Ruetten H, Allebrandt KV.

Mol Genet Metab. 2017 May;121(1):43-50. doi: 10.1016/j.ymgme.2017.03.004. Epub 2017 Mar 22.

11.

Correction: Chronic Activation of Hepatic Nrf2 Has No Major Effect on Fatty Acid and Glucose Metabolism in Adult Mice.

Brachs S, Winkel AF, Polack J, Tang H, Brachs M, Margerie D, Brunner B, Jahn-Hofmann K, Ruetten H, Spranger J, Schmoll D.

PLoS One. 2017 Feb 16;12(2):e0172657. doi: 10.1371/journal.pone.0172657. eCollection 2017.

12.

Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice.

Brachs S, Winkel AF, Tang H, Birkenfeld AL, Brunner B, Jahn-Hofmann K, Margerie D, Ruetten H, Schmoll D, Spranger J.

Mol Metab. 2016 Aug 13;5(11):1072-1082. doi: 10.1016/j.molmet.2016.08.004. eCollection 2016 Nov.

13.

Chronic Activation of Hepatic Nrf2 Has No Major Effect on Fatty Acid and Glucose Metabolism in Adult Mice.

Brachs S, Winkel AF, Polack J, Tang H, Brachs M, Margerie D, Brunner B, Jahn-Hofmann K, Ruetten H, Spranger J, Schmoll D.

PLoS One. 2016 Nov 4;11(11):e0166110. doi: 10.1371/journal.pone.0166110. eCollection 2016. Erratum in: PLoS One. 2017 Feb 16;12 (2):e0172657.

14.

Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series.

Shankar SS, Vella A, Raymond RH, Staten MA, Calle RA, Bergman RN, Cao C, Chen D, Cobelli C, Dalla Man C, Deeg M, Dong JQ, Lee DS, Polidori D, Robertson RP, Ruetten H, Stefanovski D, Vassileva MT, Weir GC, Fryburg DA; Foundation for the National Institutes of Health β-Cell Project Team.

Diabetes Care. 2016 Sep;39(9):1602-13. doi: 10.2337/dc15-0931. Epub 2016 Jul 12.

15.

Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects.

Tillner J, Lehmann A, Paehler T, Lukacs Z, Ruf S, Sadowski T, Pinquier JL, Ruetten H.

Clin Pharmacol Drug Dev. 2016 Jan;5(1):57-68. doi: 10.1002/cpdd.201. Epub 2015 Sep 24.

PMID:
27119579
16.

End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899.

Löhn M, Plettenburg O, Kannt A, Kohlmann M, Hofmeister A, Kadereit D, Monecke P, Schiffer A, Schulte A, Ruetten H, Ivashchenko Y.

World J Cardiol. 2015 Jan 26;7(1):31-42. doi: 10.4330/wjc.v7.i1.31.

17.

Female resistance to pneumonia identifies lung macrophage nitric oxide synthase-3 as a therapeutic target.

Yang Z, Huang YC, Koziel H, de Crom R, Ruetten H, Wohlfart P, Thomsen RW, Kahlert JA, Sørensen HT, Jozefowski S, Colby A, Kobzik L.

Elife. 2014 Oct 15;3. doi: 10.7554/eLife.03711.

18.

Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.

Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Schäfer A, Bauersachs J.

Basic Res Cardiol. 2014 Jul;109(4):421. doi: 10.1007/s00395-014-0421-1. Epub 2014 Jun 8.

PMID:
24907870
19.

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium.

Koivula RW, Heggie A, Barnett A, Cederberg H, Hansen TH, Koopman AD, Ridderstråle M, Rutters F, Vestergaard H, Gupta R, Herrgård S, Heymans MW, Perry MH, Rauh S, Siloaho M, Teare HJ, Thorand B, Bell J, Brunak S, Frost G, Jablonka B, Mari A, McDonald TJ, Dekker JM, Hansen T, Hattersley A, Laakso M, Pedersen O, Koivisto V, Ruetten H, Walker M, Pearson E, Franks PW; DIRECT Consortium.

Diabetologia. 2014 Jun;57(6):1132-42. doi: 10.1007/s00125-014-3216-x. Epub 2014 Apr 4.

20.

Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease.

Babelova A, Jansen F, Sander K, Löhn M, Schäfer L, Fork C, Ruetten H, Plettenburg O, Stark H, Daniel C, Amann K, Pavenstädt H, Jung O, Brandes RP.

PLoS One. 2013 Nov 7;8(11):e80328. doi: 10.1371/journal.pone.0080328. eCollection 2013.

21.
22.

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.

Wohlfart P, Linz W, Hübschle T, Linz D, Huber J, Hess S, Crowther D, Werner U, Ruetten H.

J Transl Med. 2013 Mar 28;11:84. doi: 10.1186/1479-5876-11-84.

23.

Inhibition of CatA: an emerging strategy for the treatment of heart failure.

Ruf S, Buning C, Schreuder H, Linz W, Hübschle T, Linz D, Ruetten H, Wirth K, Sadowski T.

Future Med Chem. 2013 Mar;5(4):399-409. doi: 10.4155/fmc.13.24.

PMID:
23495688
24.

Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut.

Linz D, Wirth K, Linz W, Heuer HO, Frick W, Hofmeister A, Heinelt U, Arndt P, Schwahn U, Böhm M, Ruetten H.

Hypertension. 2012 Dec;60(6):1560-7. doi: 10.1161/HYPERTENSIONAHA.112.201590. Epub 2012 Oct 29.

PMID:
23108657
25.

Effects of a novel amiodarone-like compound SAR114646A on the pig atrium and susceptibility to ventricular fibrillation in dogs and pigs.

Billman GE, Gögelein H, Ruetten H, Wirth KJ.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):373-84. doi: 10.1007/s00210-011-0716-9. Epub 2012 Jan 11.

PMID:
22234329
26.

Effects of the novel amiodarone-like compound SAR114646A on cardiac ion channels and ventricular arrhythmias in rats.

Goegelein H, Gautier P, Roccon A, O'Connor S, Ruetten H.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):231-44. doi: 10.1007/s00210-011-0664-4. Epub 2011 Jul 16.

PMID:
21766160
27.

Effect of dronedarone on Na+, Ca2+ and HCN channels.

Bogdan R, Goegelein H, Ruetten H.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Apr;383(4):347-56. doi: 10.1007/s00210-011-0599-9. Epub 2011 Jan 29.

PMID:
21279331
28.

Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation.

Schäfer A, Galuppo P, Fraccarollo D, Vogt C, Widder JD, Pfrang J, Tas P, Barbosa-Sicard E, Ruetten H, Ertl G, Fleming I, Bauersachs J.

Diabetes. 2010 Aug;59(8):2001-9. doi: 10.2337/db09-1668. Epub 2010 Jun 3.

29.

Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor.

Löhn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, Schaefer M, Linz W, Kohlmann M, Herbert JM, Janiak P, O'Connor SE, Ruetten H.

Hypertension. 2009 Sep;54(3):676-83. doi: 10.1161/HYPERTENSIONAHA.109.134353. Epub 2009 Jul 13.

PMID:
19597037
30.

The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury.

Frantz S, Adamek A, Fraccarollo D, Tillmanns J, Widder JD, Dienesch C, Schäfer A, Podolskaya A, Held M, Ruetten H, Ertl G, Bauersachs J.

Basic Res Cardiol. 2009 Nov;104(6):773-9. doi: 10.1007/s00395-009-0041-3. Epub 2009 Jun 23.

PMID:
19548059
31.

Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.

Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J.

Circulation. 2008 Aug 19;118(8):818-27. doi: 10.1161/CIRCULATIONAHA.107.717702. Epub 2008 Aug 4.

PMID:
18678774
32.

Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling.

Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hübschle T, Mang C, Strobel H, Suzuki T, Kleinert H, Förstermann U, Ruetten H, Li H.

J Pharmacol Exp Ther. 2008 May;325(2):370-9. doi: 10.1124/jpet.107.128009. Epub 2008 Feb 5.

PMID:
18252813
33.

Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects.

Bauersachs J, Hiss K, Fraccarollo D, Laufs U, Ruetten H.

Cardiovasc Res. 2006 Dec 1;72(3):438-46. Epub 2006 Aug 30.

PMID:
17026973
34.
35.

Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.

Ruetten H, Gehring D, Hiss K, Schindler U, Gerl M, Busch AE, Schaefer S.

Br J Pharmacol. 2005 Nov;146(5):723-31.

36.

Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload.

Ruetten H, Dimmeler S, Gehring D, Ihling C, Zeiher AM.

Cardiovasc Res. 2005 Jun 1;66(3):444-53. Epub 2005 Feb 24.

PMID:
15914109
37.

Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc.

Heineke J, Ruetten H, Willenbockel C, Gross SC, Naguib M, Schaefer A, Kempf T, Hilfiker-Kleiner D, Caroni P, Kraft T, Kaiser RA, Molkentin JD, Drexler H, Wollert KC.

Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1655-60. Epub 2005 Jan 21.

38.

Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction.

Rungwerth K, Schindler U, Gerl M, Schäfer S, Licher T, Busch AE, Ruetten H.

Br J Pharmacol. 2004 Aug;142(7):1147-54. Epub 2004 Jul 5.

39.

Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload.

Badorff C, Ruetten H, Mueller S, Stahmer M, Gehring D, Jung F, Ihling C, Zeiher AM, Dimmeler S.

J Clin Invest. 2002 Feb;109(3):373-81.

40.

Inhibition of caspase-3 improves contractile recovery of stunned myocardium, independent of apoptosis-inhibitory effects.

Ruetten H, Badorff C, Ihling C, Zeiher AM, Dimmeler S.

J Am Coll Cardiol. 2001 Dec;38(7):2063-70.

41.
42.

Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice.

Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, Ceiler D, Gehring D, Martins I, Salmon G, Boulanger CM, Nussberger J, Crozatier B, Gasc JM, Heudes D, Bruneval P, Doetschman T, Ménard J, Alhenc-Gelas F.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2634-9. Epub 2001 Feb 20.

43.

Inhibition of endogenous nitric oxide synthase potentiates ischemia-reperfusion-induced myocardial apoptosis via a caspase-3 dependent pathway.

Weiland U, Haendeler J, Ihling C, Albus U, Scholz W, Ruetten H, Zeiher AM, Dimmeler S.

Cardiovasc Res. 2000 Feb;45(3):671-8.

PMID:
10728388
45.

Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.

Wohlfart P, Malinski T, Ruetten H, Schindler U, Linz W, Schoenafinger K, Strobel H, Wiemer G.

Br J Pharmacol. 1999 Nov;128(6):1316-22.

46.

Ramiprilat prevents the development of acute coronary endothelial dysfunction in the dog.

Martorana PA, Ruetten H, Goebel B, Koehl D, Roegner B, Schoelkens BA, Keil M.

Basic Res Cardiol. 1999 Aug;94(4):238-45.

PMID:
10505423
47.

Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats.

Ruetten H, Zabel U, Linz W, Schmidt HH.

Circ Res. 1999 Sep 17;85(6):534-41.

PMID:
10488056
48.

Reduction of myocardial reperfusion injury by an inhibitor of poly (ADP-ribose) synthetase in the pig.

Bowes J, Ruetten H, Martorana PA, Stockhausen H, Thiemermann C.

Eur J Pharmacol. 1998 Oct 23;359(2-3):143-50.

PMID:
9832385
49.

Coronary endothelial dysfunction after ischemia and reperfusion in the dog: a functional and morphological investigation.

Martorana PA, Goebel B, Ruetten H, Koehl D, Keil M.

Basic Res Cardiol. 1998 Aug;93(4):257-63.

PMID:
9782367

Supplemental Content

Loading ...
Support Center